Merck registers Phase 3 trial of MK-8748 in macular edema after retinal vein occlusion
Merck Sharp & Dohme LLC has posted a new Phase 2/3 study to evaluate intravitreal MK-8748 versus aflibercept in participants with macular edema following retinal vein occlusion. The study plans to enroll 1188 participants and is expected to begin on December 21, 2026.
Primary source
ClinicalTrials.gov registry record, November 20, 2026
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Macular Edema After Retinal Vein Occlusion (MK-8748-006)
Read the source: A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Macular Edema After Retinal Vein Occlusion (MK-8748-006) clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation